WBB Securities

Why is the 2026 Ebola outbreak raising new concerns? Dr. Steve Brozak examines institutional distrust, attacks on healthcare infrastructure, delayed containment efforts, and global preparedness. Read here via @forbes forbes.com/sites/stephenb… #Ebola #GlobalHealth

A WHO emergency meeting. Multiple countries monitoring cases. Questions about transmission, preparedness, and containment. In @forbeshealth, Dr. Steve Brozak examines 5 urgent questions emerging from the recent Hantavirus outbreak. Read here: forbes.com/sites/stephenb… #Hantavirus

Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and psychiatric overprescribing and what can be done moving forward. "Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing" via @forbes forbes.com/sites/stephenb…

WBB Sec President Dr Steve Brozak is moderating today’s #BiotechShowcase panel: “Working with ARPA-H: Federal Investment in Biotech & Healthcare Innovation.” Featuring ARPA-H leaders: Dr Jessica Green, Natalie Kates & Dr Paul Sheehan. 🔗 #biotech-showcase-imperial-ballroom_working-with-arpa-h-federal-investment-in-biotech-healthcare-innovation_17-30" target="_blank" rel="nofollow noopener">informaconnect.com/biotech-showca… #BiotechShowcase

The US healthcare system faces a real stress test in 2026. In @Forbes, Dr Brozak examines how the potential ACA subsidy cliff exposes deeper structural risks in healthcare’s business model, from incentives to access to rising costs. Read more via @forbes forbes.com/sites/stephenb…

OYE Therapeutics raises $5.475M Series A to advance high-concentration caffeine therapy for anesthesia recovery & OIRD. WBB Securities acted as placement agent. Phase 1 planned for Q1 2026. Congrats to the OYE team on reaching this important milestone. 🔗oyetherapeutics.reportablenews.com/pr/oye-raises-…

Dr. Brozak describes why it’s critical to understand the role that Medicaid and Medicaid State-directed payments (SDPs) play in the survival of what are known as Safety Net Hospitals and the entire US Healthcare System. Via @Forbes forbes.com/sites/stephenb…

WBB Securities acted as sole placement agent in #FELIQSCorp’s $9M Series A to advance FLQ-101, a novel treatment to prevent blindness in premature infants. #Biotech #ROP 🔗 feliqs.reportablenews.com/pr/feliqs-anno…

🎉 💬 We’re hosting our 50th complimentary #VirtualSalon w/a timely discussion on CD19 CAR-T therapies & their impact since @US_FDA approval. I would love for you to join us on May 28, from 11:00 AM – 12:00 PM ET. 👉 Complimentary registration: bit.ly/3Ed22d5

Seven years after the FDA's first approval, what have we learned about #CellTherapy and #GeneTherapy? Join the conversation at the @DemyColton Virtual Salon 🔗 conference.demy-colton.com/seven-years-af… #Biotech #FDA #Innovation #LifeSciences #WBB

President Donald Trump – Will He Become The Drug Price Equalizer? via @forbes by Dr. Steve Brozak, WBB Sec. – Why US drugs are the world’s costliest and how Most Favored Nation will affect the pharma industry. forbes.com/sites/stephenb…

Tariffs on pharmaceuticals could reshape the industry. In his latest @Forbes article, Dr. Steve Brozak examines how the U.S. dodged a bullet—for now. But can domestic manufacturing step up? Read more: forbes.com/sites/stephenb… #Pharma #Biotech #Healthcare #DrugShortages #Forbes

What will new tariffs mean for drug prices & availability? In his latest @Forbes piece, WBB Securities’ President Dr. Steve Brozak explores what’s ahead for pharma & the supply chain. Read more: @forbes forbes.com/sites/stephenb… #DrugPricing #Tariffs #Pharma #Healthcare

A Biotech Showcase panel convened to discuss the threat of H5N1 after the announcement of the first confirmed human case of bird flu. Only through innovative strategies will the threats of infections by H5N1 and other pathogens be effectively addressed forbes.com/sites/stephenb…

The panel, moderated by Dr. Steve Brozak, includes Dr. Jeffrey Stein, Pres. & CEO of @CidaraThera, Emma Wheatley, Executive Director Access & Business Development, @CEPIvaccines, Dr. Phillip Chan, CEO of @CytoSorbents, and Dr. Niels Riedemann, CEO & Founder of @InflaRx N.V.

A #BiotechShowcase panel at 8:00 am PT tomorrow will address the evolution of life-threatening pathogens like H5N1. With the just-announced first U.S. case of H5N1 in a child in San Fran, the need for novel responses to disease threats in a fast-changing world has become critical

Panelists include: 👉 Dr. Jeffrey Stein @CidaraThera 👉 Emma Wheatley @CEPIvaccines 👉 Dr. Phillip Chan @CytoSorbents 👉 Dr. Niels Riedemann @InflaRx The discussion will highlight solutions for tackling emerging health challenges in a rapidly changing world @demy_sara @EBDgroup

Tomorrow at 8:00 AM PT, a #BiotechShowcase panel will explore innovative solutions to global threats like #H5N1 Bird Flu. With the first U.S. case of a child reported in SF, addressing these challenges has never been more critical. Moderated by Dr. Steve Brozak

President Biden’s @POTUS healthcare initiatives have under-delivered on their promises. Dr. Steve Brozak’s latest article in Forbes describes "Biden’s 2024 Healthcare Legacy: Was It A Failure Of More Than Messaging?" via @forbes forbes.com/sites/stephenb…

Wall Street analyst @wbbsec argues RFK may be "just what the doctor ordered" to improve America's ailing health care system. forbes.com/sites/stephenb…